Andere talen AstraZeneca Pharma India Limited NSE India S.E.

Aandelen

ASTRAZEN

INE203A01020

Beurs gesloten - NSE India S.E. Andere beurzen 13:43:51 22-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5.753 ^INR	-0,51%		+5,42%	+4,10%

08/04	AstraZeneca Pharma India Limited hecht goedkeuring aan de benoeming van Bhavana Agrawal tot directeur en Whole Time Director	CI
25/03	AstraZeneca Pharma India Limited benoemt Vinay Sharma tot Business Unit Head - Zeldzame Ziekten, met ingang van 1 juli 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

AstraZeneca Pharma India Limited Approves Appointment of Bhavana Agrawal as Director and Whole Time Director	08/04
AstraZeneca Pharma India Limited Appoints Vinay Sharma as Business Unit Head - Rare Disease, Effective July 1, 2024	25/03
AstraZeneca, Mankind Pharma Tie Up for Exclusive Distribution of Asthma Drug Symbicort in India	11/03
Astrazeneca Pharma India Ltd and Mankind Pharma Partner to Accelerate Access to Asthma Medicine for Patients in India	11/03
Astrazeneca Pharma India Limited Announces Board Changes	20/02
AstraZeneca Pharma India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02
AstraZeneca Pharma India Limited Announces Board Changes	08/02
AstraZeneca Pharma India Limited Announces Directorate Appointments	07/02
AstraZeneca Gets Indian Drug Regulator's Nod to Import Andexanet Alfa Powder for Solution for Infusion	22/01
Astrazeneca Pharma to Launch Breast Cancer Treatment Drug in India in January 2024	21/12
India's Nifty set for muted open after steep drop	21/12
Astrazeneca Pharma India Limited Appoints Hooi-Bien Chuah as Additional Director (Non-Executive)	09/11
AstraZeneca Pharma India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
AstraZeneca Gets Indian Drug Regulator's Nod to Import Pharmaceutical Formulations for Palivizumab	02-10-23
Astrazeneca Pharma India Limited Receives Permission to Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For Palivizumab	30-09-23
AstraZeneca Pharma India Limited Announces Management Changes	29-09-23
Astrazeneca Pharma India Limited Announces Retirement of Rajesh Marwaha as Whole-Time Director	29-09-23
AstraZeneca Pharma India Limited Appoints Praveen Akkinepally as the Business Unit Head Oncology with Effect from November 1, 2023	15-09-23
AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2022-2023	17-08-23
AstraZeneca Pharma India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen AstraZeneca Pharma India Limited NSE India S.E.

Aandelen

ASTRAZEN

INE203A01020

Andere talen

Filters